Related references
Note: Only part of the references are listed.The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
M. Haas et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation
Marieke van der Zwan et al.
CLINICAL PHARMACOKINETICS (2018)
Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation - a retrospective study
Michelle Willicombe et al.
TRANSPLANT INTERNATIONAL (2017)
Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression
M. F. Nijhoff et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients
Robert R. Redfield et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Pretransplant human leukocyte antigen antibodies detected by single-antigen bead assay are a risk factor for long-term kidney graft loss even in the absence of donor-specific antibodies
Rudolf Richter et al.
TRANSPLANT INTERNATIONAL (2016)
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial
Richard Haynes et al.
LANCET (2014)
Analysis of Predictive and Preventive Factors for De Novo DSA in Kidney Transplant Recipients
Toshihito Hirai et al.
TRANSPLANTATION (2014)
Antithymocyte Globulin Is Associated With a Lower Incidence of De Novo Donor-Specific Antibodies in Moderately Sensitized Renal Transplant Recipients
Marissa M. Brokhof et al.
TRANSPLANTATION (2014)
Alemtuzumab and Minimization Immunotherapy in Kidney Transplantation: Long-Term Results of Comparison With Rabbit Anti-Thymocyte Globulin and Standard Triple Maintenance Therapy
M. Zachariah et al.
TRANSPLANTATION PROCEEDINGS (2014)
Incidence and Management of Leukopenia/Neutropenia in 233 Kidney Transplant Patients Following Single Dose Alemtuzumab Induction
A. Smith et al.
TRANSPLANTATION PROCEEDINGS (2014)
In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development
Marta Todeschini et al.
JOURNAL OF IMMUNOLOGY (2013)
Alemtuzumab Induction Therapy in Kidney Transplantation: A Systematic Review and Meta-Analysis
Robert D. Morgan et al.
TRANSPLANTATION (2012)
Desensitization Protocols and Their Outcome
Kwaku Marfo et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Alemtuzumab Induction in Renal Transplantation
Michael J. Hanaway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation
Junichiro Sageshima et al.
TRANSPLANT IMMUNOLOGY (2011)
Single Dose of Alemtuzumab Induction With Steroid-Free Maintenance Immunosuppression in Pancreas Transplantation
Tadahiro Uemura et al.
TRANSPLANTATION (2011)
Sensitized renal transplant recipients: current protocols and future directions
James Gloor et al.
NATURE REVIEWS NEPHROLOGY (2010)
Randomized Trial of Thymoglobulin Versus Alemtuzumab (with Lower Dose Maintenance Immunosuppression) Versus Daclizumab in Living Donor Renal Transplantation
G. Ciancio et al.
TRANSPLANTATION PROCEEDINGS (2010)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
A Randomized Trial of Alemtuzumab Versus Antithymocyte Globulin Induction in Renal and Pancreas Transplantation
Alan C. Farney et al.
TRANSPLANTATION (2009)
Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up
Menna R. Clatworthy et al.
TRANSPLANTATION (2009)
Alemtuzumab (campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial
R. Margreiter et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond
M. Mohty
LEUKEMIA (2007)
Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation
Philip G. Thomas et al.
TRANSPLANTATION (2007)
Share Paper
